DESTINY-Breast03 Phase 3 Study Results
DESTINY-Breast03 PRO &
Hospitalization Endpoints & Analyses
Endpoint
EORTC QLQ-C30
Description
Oncology-specific
questionnaire
.
Measures of interest
Global health status (GHS)/QoLa
Functioning scales: physical, role, emotional,
cognitive, and social
Symptom scales: pain
Symptom scales: arm and breast
DESTINY-Breast03
Daiichi-Sankyo
Main analyses
•
Change from baseline
•
Time to definitive deterioration
(TDD)b,c
EORTC QLQ-BR45
Breast cancer-specific
questionnaire
TDDb,c
EQ-5D-5L
Generic questionnaire
•
Hospitalization
Records assessment
Self-rated health status (visual analog scale [VAS])
Date of admission to hospital
Status/date of discharge
•
TDDC
•
Time to first hospitalization
•
Length of stay
Completion compliance for HRQoL patient questionnaires was high in both treatment groups, with >97% completion at
baseline and >82% completion from cycles 3-27 in both arms
EORTC, European Organization for Research and Treatment of Cancer; EQ-5D-5L, EuroQol 5-dimension, 5-level questionnaire; GHS, global health status; HRQoL, health-related
quality of life; PRO, patient-reported outcome; QLQ-BR45, Quality of Life Breast cancer questionnaire; QLQ-C30, Quality of Life Core 30 questionnaire; T-DM1, trastuzumab emtansine;
T-DXd, trastuzumab deruxtecan.
aPrimary PRO variable of interest. Clinically meaningful deterioration defined as a change of 10 points or more in the GHS and subscale scores. Not all variables measured were
assessed for TDD.
ESMO BC 2022 #1630 Oral
41View entire presentation